Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer

Inclusion Criteria: 1. Histopathology or cytopathology proven gastric cancer or gastroesophageal adenocarcinoma; 2. Locally advanced, or recurrent, or metastasis disease； 3. Chemotherapy-naive or disease progress at least 6 months after adjuvant chemotherapy completed; 4. Life expectancy of at least 3 months; 5. ECOG score 0-1; 6. Age: 18\~70 years old; 7. Normal hemodynamic indices before the recruitment (including blood cell count and liver/kidney function). For example: WBC\>4.0×109/L, NEU \>1.5×109/L, PLT\>100×109/L, BIL\<1.5 times of upper limit of normal reference value, ALT and AST\<2.5 times of upper limit of normal reference value, and CRE\<1.2mg/dl; 8. Good cardiac function before the recruitment, no seizure of myocardial infarction in past half year, and controllable hypertension and other coronary heart diseases; 9. Not concomitant with other uncontrollable benign diseases before the recruitment (e.g. the infection in the lung, kidney and liver); 10. Not participating in other study projects before and during the treatment; 11. Voluntarily signed the informed consent. Exclusion Criteria: 1. Previously treated with first-line chemotherapy; 2. Allergy to the drugs in this protocol; 3. Pregnant or lactating women; 4. Women at childbearing age and of pregnancy desire during the study.